Chitosan Scaffold Containing Periostin Enhances Sternum Bone Healing and Decreases Serum Level of TNF-α and IL-6 after Sternotomy in Rat.
Bone healing
Chitosan
OPG and RANKL
Periostin
Runx2
Journal
Tissue engineering and regenerative medicine
ISSN: 2212-5469
Titre abrégé: Tissue Eng Regen Med
Pays: Korea (South)
ID NLM: 101699923
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
19
11
2021
accepted:
12
01
2022
revised:
11
01
2022
pubmed:
25
2
2022
medline:
22
7
2022
entrez:
24
2
2022
Statut:
ppublish
Résumé
In the aftermath of bone injuries, such as cranium and sternum, bone wax (BW) is used to control bleeding from the bone surfaces during surgery. Made up of artificial substances, however, it is associated with many complications such as inflammation, increased risk for infection, and bone repair delay. We, therefore, in this study set out to design and evaluate a novel BW without the above-mentioned side-effects reported for other therapies. The pastes (new BW(s)) were prepared in the laboratory and examined by MTT, MIC, MBC, and degradability tests. Then, 60 adult male Wistar rats, divided into six equal groups including chitosan (CT), CT-octacalcium phosphate (OCP), CT-periostin (Post), CT-OCP-Post, Control (Ctrl), and BW, underwent sternotomy surgery. Once the surgeries were completed, the bone repair was assessed radiologically and thereafter clinically in vivo and in vitro using CT-scan, H&E, ELISA, and qRT-PCR. All pastes displayed antibacterial properties and the CT-Post group had the highest cell viability compared to the control group. In contrast to the BW, CT-Post group demonstrated weight changes in the degradability test. In the CT-Post group, more number of osteocyte cells, high trabeculae percentage, and the least fibrous connective tissue were observed compared to other groups. Additionally, in comparison to the CT and Ctrl groups, higher alkaline phosphatase activity, as well as decreased level of serum tumor necrosis factor-α, interleukin-6, and OCN in the CT-Post group was evident. Finally, Runx2, OPG, and RANKL genes' expression was significantly higher in the CT-Post group than in other groups. Our results provide insights into the desirability of pastes in terms of cellular viability, degradability, antibacterial properties, and surgical site restoration compared to the BW group. Besides, Periostin could enhance the osteogenic properties of bone tissue defect site.
Sections du résumé
BACKGROUND
In the aftermath of bone injuries, such as cranium and sternum, bone wax (BW) is used to control bleeding from the bone surfaces during surgery. Made up of artificial substances, however, it is associated with many complications such as inflammation, increased risk for infection, and bone repair delay. We, therefore, in this study set out to design and evaluate a novel BW without the above-mentioned side-effects reported for other therapies.
METHODS
The pastes (new BW(s)) were prepared in the laboratory and examined by MTT, MIC, MBC, and degradability tests. Then, 60 adult male Wistar rats, divided into six equal groups including chitosan (CT), CT-octacalcium phosphate (OCP), CT-periostin (Post), CT-OCP-Post, Control (Ctrl), and BW, underwent sternotomy surgery. Once the surgeries were completed, the bone repair was assessed radiologically and thereafter clinically in vivo and in vitro using CT-scan, H&E, ELISA, and qRT-PCR.
RESULTS
All pastes displayed antibacterial properties and the CT-Post group had the highest cell viability compared to the control group. In contrast to the BW, CT-Post group demonstrated weight changes in the degradability test. In the CT-Post group, more number of osteocyte cells, high trabeculae percentage, and the least fibrous connective tissue were observed compared to other groups. Additionally, in comparison to the CT and Ctrl groups, higher alkaline phosphatase activity, as well as decreased level of serum tumor necrosis factor-α, interleukin-6, and OCN in the CT-Post group was evident. Finally, Runx2, OPG, and RANKL genes' expression was significantly higher in the CT-Post group than in other groups.
CONCLUSION
Our results provide insights into the desirability of pastes in terms of cellular viability, degradability, antibacterial properties, and surgical site restoration compared to the BW group. Besides, Periostin could enhance the osteogenic properties of bone tissue defect site.
Identifiants
pubmed: 35199306
doi: 10.1007/s13770-022-00434-8
pii: 10.1007/s13770-022-00434-8
pmc: PMC9294132
doi:
Substances chimiques
Anti-Bacterial Agents
0
Biocompatible Materials
0
Cell Adhesion Molecules
0
Interleukin-6
0
Tumor Necrosis Factor-alpha
0
Chitosan
9012-76-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
839-852Informations de copyright
© 2022. The Korean Tissue Engineering and Regenerative Medicine Society.
Références
Cytokine Growth Factor Rev. 2004 Feb;15(1):49-60
pubmed: 14746813
J Bone Miner Res. 2017 Jul;32(7):1432-1441
pubmed: 28322464
Biomark Res. 2017 May 18;5:18
pubmed: 28529755
Nat Commun. 2018 Feb 22;9(1):773
pubmed: 29472541
Mol Med Rep. 2018 May;17(5):6605-6611
pubmed: 29512766
Proc Nutr Soc. 2008 May;67(2):157-62
pubmed: 18412989
Connect Tissue Res. 2018 Mar;59(2):108-119
pubmed: 28301220
Pathology. 2006 Apr;38(2):138-41
pubmed: 16581654
Lancet. 2011 Apr 9;377(9773):1276-87
pubmed: 21450337
Calcif Tissue Int. 2005 Jan;76(1):1-6
pubmed: 15455183
J Control Release. 2017 May 28;254:65-74
pubmed: 28363521
Int J Food Microbiol. 2010 Nov 15;144(1):51-63
pubmed: 20951455
J Biomed Mater Res B Appl Biomater. 2020 Jan;108(1):243-252
pubmed: 30980703
Biomaterials. 2018 Nov;182:58-71
pubmed: 30107270
J Antimicrob Chemother. 2008 Dec;62(6):1339-43
pubmed: 18799473
Ann Thorac Surg. 2018 Jul;106(1):298-304
pubmed: 29577921
J Craniofac Surg. 2018 Jun;29(4):976-979
pubmed: 29438209
Bone. 2015 Feb;71:94-100
pubmed: 25445447
Ann Thorac Surg. 2004 Jan;77(1):203-9
pubmed: 14726062
J Mol Histol. 2019 Dec;50(6):493-502
pubmed: 31522346
J Biol Chem. 2004 Apr 30;279(18):18361-9
pubmed: 14970229
Interact Cardiovasc Thorac Surg. 2003 Dec;2(4):410-2
pubmed: 17670085
Biomed Pharmacother. 2018 Jun;102:369-374
pubmed: 29571022
Eur J Clin Nutr. 2017 Jan;71(1):56-63
pubmed: 27650875
Ann Thorac Surg. 2008 May;85(5):1776-80
pubmed: 18442583
Osteoporos Int. 2000;11(1):31-5
pubmed: 10663356
Osteoporos Int. 2012 Apr;23(4):1199-212
pubmed: 22310955
Medicine (Baltimore). 2017 Jan;96(4):e5780
pubmed: 28121926
Calcif Tissue Int. 1985 Mar;37(2):194-7
pubmed: 3924374
Toxicol Appl Pharmacol. 2018 Mar 15;343:62-70
pubmed: 29477364
Ann Thorac Surg. 2015 Mar;99(3):1005-11
pubmed: 25601654
PLoS One. 2015 Mar 16;10(3):e0116698
pubmed: 25775460
J Bone Miner Res. 1994 Mar;9(3):423-9
pubmed: 8191937
J Biol Chem. 2009 Dec 18;284(51):35939-50
pubmed: 19837663
J Cell Physiol. 2009 Mar;218(3):584-92
pubmed: 19006175
Future Sci OA. 2018 Jul 26;4(8):FSO326
pubmed: 30271614
Osteoporos Int. 2016 Feb;27(2):769-79
pubmed: 26194493
Immune Netw. 2018 Feb 07;18(1):e8
pubmed: 29503739
Sci Rep. 2017 Jan 27;7:41634
pubmed: 28128364
Bone. 2017 Jun;99:8-13
pubmed: 28323143
Acta Biomater. 2016 Mar;33:252-63
pubmed: 26805427
Int J Food Microbiol. 2002 Mar 25;74(1-2):65-72
pubmed: 11929171
Mol Biol Rep. 2016 Oct;43(10):1179-91
pubmed: 27401061
Arch Oral Biol. 2017 Aug;80:56-61
pubmed: 28384521